The content on this site is intended for healthcare professionals only
Prof Dimopoulos presents findings during a press conference at the ASH 2012 Annual Meeting in Atlanta, Georgia on pomalidomidedata with low-dose vs. high-dose dexamathasone in refractory patients, and the pomalidomide data with numerous newer agents. Also data with the oral proteasome inhibitors, such as MLN9708, and novel monoclonal antibody agents, such as daratumumab.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
EHA 2024: Multiple myeloma roundup
